• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?

    Simply Wall St·08/20/2026 23:25:02
    Listen to the news
    • In August 2026, Abbott Laboratories reported stronger-than-expected fiscal Q2 results and raised its annual profit forecast, driven largely by robust demand for cancer diagnostics and medical devices.
    • This earnings outperformance highlights the importance of Abbott's diversified healthcare portfolio, where diagnostics and devices together underpin both growth and resilience.
    • Next, we’ll examine how this earnings beat and upgraded profit outlook interact with Abbott’s existing investment narrative and growth assumptions.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Abbott Laboratories Investment Narrative Recap

    To own Abbott, you need to believe in the durability of its diversified healthcare portfolio, especially diagnostics and medical devices, as core earnings drivers. The Q2 2026 beat and higher profit forecast reinforce that view in the near term, while competition and pricing pressure in continuous glucose monitoring remain a central risk that could blunt the impact of new product wins and partnerships if they do not translate into sustained, profitable demand.

    The new partnership with Google Health around Abbott’s Lingo biowearable is particularly relevant here, because it directly ties Abbott’s glucose sensing capabilities into a broader AI-enabled health platform. For investors focused on catalysts, this highlights how Abbott is trying to deepen the role of continuous glucose and metabolic monitoring in everyday health decisions, at the same time that reimbursement, pricing and competitive dynamics are front of mind for the diabetes and wearable sensor franchise.

    However, against this positive backdrop, investors should also be aware that...

    Read the full narrative on Abbott Laboratories (it's free!)

    Abbott Laboratories’ narrative projects $60.4 billion revenue and $9.5 billion earnings by 2029. This requires 9.0% yearly revenue growth and an earnings increase of about $4.1 billion from $5.4 billion today.

    Uncover how Abbott Laboratories' forecasts yield a $119.12 fair value, a 4% upside to its current price.

    Exploring Other Perspectives

    ABT 1-Year Stock Price Chart
    ABT 1-Year Stock Price Chart

    Five members of the Simply Wall St Community see Abbott’s fair value between US$119 and US$151, showing a wide span of individual estimates. You can weigh those views against the current concern that pricing pressure and competition in continuous glucose monitoring could limit how much partnerships like Google Health ultimately contribute to Abbott’s performance.

    Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $119.12!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.